Portopulmonary hypertension and hepatopulmonary syndrome: A clinician-oriented overview

European Respiratory Review

Volumn 21, Issue 125, 2012, Pages 223-233

  Porres Aguilar, Mateo ^a   Altamirano, Jose T ^b   Torre Delgadillo, Aldo ^c   Charlton, Michael R ^d   Duarte Rojo, Andres ^e  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d HOSPITAL CLÍNIC   (Spain)

^e INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Cirrhosis; Hepatopulmonary syndrome; Liver transplantation; Portal hypertension; Portopulmonary hypertension; Pulmonary hypertension

Indexed keywords

AMBRISENTAN; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; ILOPROST; MACROSALB TC 99M; METHYLENE BLUE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NORFLOXACIN; OXYGEN; PENTOXIFYLLINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SPIRONOLACTONE; TADALAFIL;

ARTERIAL GAS; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; COUGHING; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FLUSHING; HEADACHE; HEART CATHETERIZATION; HEART RIGHT VENTRICLE FAILURE; HEPATOPULMONARY SYNDROME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPOXEMIA; LIVER TRANSPLANTATION; LUNG ANGIOGRAPHY; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; LUNG SCINTISCANNING; LUNG VASCULAR RESISTANCE; MEDICAL DECISION MAKING; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT SELECTION; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PRACTICE GUIDELINE; PROGNOSIS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THORAX RADIOGRAPHY; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION;

ARTERIAL PRESSURE; HEMODYNAMICS; HEPATOPULMONARY SYNDROME; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER CIRCULATION; PROGNOSIS; PULMONARY CIRCULATION; RISK FACTORS; VASCULAR RESISTANCE; VASODILATION;

EID: 84865726568     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00007211     Document Type: Review

References (97)

1. Porres-Aguilar M, Zuckerman MJ, Figueroa-Casas JB, et al. Portopulmonary hypertension: state of the art. Ann Hepatol 2008; 7: 321-330.
2. Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007; 28: 203-218.
3. Savale L, O'Callaghan DS, Magnier R, et al. Current management approaches to portopulmonary hypertension. Int J Clin Pract Suppl 2011; 169: 11-18.
4. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43-S54.
5. Porres-Aguilar M. Emphasizing the importance of the clinical classification for pulmonary hypertension. Ann Hepatol 2009; 8: 267-268.
6. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127: 437-441.
7. Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196-203.
8. Ramsay MA, Simpson BR, Nguyen AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997; 3: 494-500.
9. Krowka MJ, Swanson KL, Frantz RP, et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44: 1502-1510.
10. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 2010; 122: 164-172.
11. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004; 351: 1655-1665.
12. Hervé P, Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153-1166.
13. Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52: 1355-1362.
14. Neuhofer W, Gulberg V, Gerbes AL. Endothelin and endothelin receptor antagonism in portopulmonary hypertension. Eur J Clin Invest 2006; 36: Suppl. 3, 54-61.
15. Kéreveur A, Callebert J, Humbert M, et al. High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 2000; 20: 2233-2239.
16. Hervé P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-254.
17. Roberts KE, Fallon MB, Krowka MJ, et al. Serotonin transporter polymorphisms in patients with portopulmonary hypertension. Chest 2009; 135: 1470-1475.
18. Roberts KE, Fallon MB, Krowka MJ, et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835-842.
19. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159: 1925-1932.
20. Huffmyer JL, Nemergut EC. Respiratory dysfunction and pulmonary disease in cirrhosis and other hepatic disorders. Respir Care 2007; 52: 1030-1036.
21. Moller S, Henriksen JH. Cardiopulmonary complications in chronic liver disease. World J Gastroenterol 2006; 12: 526-538.
22. Kuo PC, Plotkin JS, Gaine S, et al. Portopulmonary hypertension and the liver transplant candidate. Transplantation 1999; 67: 1087-1093.
23. Swanson KL, Krowka MJ. Arterial oxygenation associated with portopulmonary hypertension. Chest 2002; 121: 1869-1875.
24. Colle IO, Moreau R., Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401-409.
25. Murray KF, Carithers RL. AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 2005; 41: 1407-1432.
26. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
27. Krowka MJ. Portopulmonary hypertension: diagnostic advances and caveats. Liver Transpl 2003; 9: 1336-1337.
28. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000; 6: 453-458.
29. Rodríguez-Roisin R, Krowka MJ, Hervé P, et al. Pulmonary-Hepatic vascular Disorders (PHD). Eur Respir J 2004; 24: 861-880.
30. Swanson KL, Krowka MJ. Screen for portopulmonary hypertension, especially in liver transplant candidates. Cleve Clin J Med 2008; 75: 121-136.
31. Robalino BD, Moodey DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory, and hemodynamic manifestations. J Am Coll Cardiol 1991; 17: 492-498.
32. Le Pavec J, Souza R, Herve P, et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178: 637-643.
33. Swanson K, Wiesner R, Nyberg S, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445-2453.
34. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111.
35. Montani D, Savale L, Natali D, et al. Long-term response to calcium channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31: 1898-1907.
36. Ota K, Shijo H, Kokawa H, et al. Effects of nifedipine on hepatic venous pressure gradient and portal vein blood flow in patients with cirrhosis. J Gastroenterol Hepatol 1995; 10: 198-204.
37. Provencher S, Herve P, Jais X, et al. Deleterious effects of betablockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130: 120-126.
38. Vera-Lastra O, Porres-Aguilar M. Pulmonary arterial hypertension associated with systemic sclerosis: current diagnostic approach and therapeutic strategies. World J Rheumatol 2012; (In press).
39. Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-648.
40. Sussman N, Kaza V, Barshes N, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transpl 2006; 6: 2177-2182.
41. Fix OK, Bass NM, De Marco T, et al. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007; 13: 875-885.
42. Halank M, Marx C, Usicenko S, et al. Inhaled iloprost for patients with portopulmonary hypertension. Am J Respir Crit Care Med 2003; A277.
43. Minder S, Fischler M, Muellhaupt B, et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004; 24: 703-707.
44. Melgosa MT, Ricci GL, García-Pagan JC, et al. Acute and long-term effects of inhaled iloprost in portopulmonary hypertension. Liver Transpl 2010; 16: 348-356.
45. Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005; 25: 502-508.
46. Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. Chest 2011; 139: 109-114.
47. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
48. Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
49. Reichenberger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28: 563-567.
50. Krowka MJ, Swanson KL. How should we treat portopulmonary hypertension? Eur Respir J 2006; 28: 466-467.
51. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10: 174-182.
52. Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transplant 2000; 6: 443-450.
53. Krowka MJ, Fallon MB, Mulligan DC, et al. Model for end-stage pulmonary disease (MELD) exception in for portopulmonary hypertension. Liver Transpl 2006; 12: Suppl. 3, S114-S116.
54. Ashfaq M, Chinnakotla S, Rogers L, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transpl 2007; 7: 1258-1264.eHeal.
55. Raval Z, Harinstein ME, Skaro AI, et al. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol 2011; 58: 223-231.
56. Bandara M, Gordon FD, Sarwar A, et al. Successful outcomes following living donor liver transplantation for portopulmonary hypertension. Liver Transpl 2010; 16: 983-989.
57. Rafanan AL, Maurer J, Mehta AC, et al. Progressive portopulmonary hypertension after liver tranplasntation treated with epoprostenol. Chest 2000; 118: 1497-1500.
58. Rodriguez-Roisin R, Krowka MJ. Hepatopulmonary syndrome - a liver-induced lung vascular disorder. N Engl J Med 2008; 29: 2378-2387.
59. Krowka MJ, Porayko MK, Plevak DJ, et al. Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. Mayo Clin Proc 1997; 72: 44-53.
60. Schenk P, Schoniger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003; 125: 1042-1052.
61. Arguedas MR, Singh H, Faulk DK, et al. Utility of pulse oximetry screening for hepatopulmonary syndrome. Clin Gastroenterol Hepatol 2007; 5: 749-754.
62. Deibert P, Allgaier HP, Loesch S, et al. Hepatopulmonary syndrome in patients with chronic liver disease: role of pulse oximetry. BMC Gastroenterol 2006; 6: 15.
63. Santa-Cruz RA, Pearson MD, Cohen MG, et al. Clinical predictors and characteristics of patients with chronic liver disease and intrapulmonary shunts. Clin Cardiol 2005; 28: 437-441.
64. Lenci I, Alvior A, Manzia TM, et al. Saline contrast echocardiography in patients with hepatopulmonary syndrome awaiting liver transplantation. J Am Soc Echocardiogr 2009; 22: 89-94.
65. Fallon MB, Krowka MJ, Brown RS, et al. Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology 2008; 135: 1168-1175.
66. Kochar R, Nevah Rubin MI, Fallon MB. Pulmonary complications of cirrhosis. Curr Gastroenterol Rep 2011; 13: 34-39.
67. Vachiéry F, Moreau R, Hadengue A, et al. Hypoxemia in patients with cirrhosis: relationship with liver failure and hemodynamic alterations. J Hepatol 1997; 27: 492-495.
68. Schenk P, Fuhrmann V, Madl C, et al. Hepatopulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. Gut 2002; 51: 853-859.
69. Rodríguez-Roisin R, Agustí AG, Roca J. The hepatopulmonary syndrome: new name, old complexities. Thorax 1992; 47: 897-902.
70. Nunes H, Lebrec D, Mazmanian M, et al. Role of nitric oxide in hepatopulmonary syndrome in cirrhotic rats. Am J Respir Crit Care Med 2001; 164: 879-885.
71. Rabiller A, Nunes H, Lebrec D, et al. Prevention of Gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med 2002; 166: 514-517.
72. + macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med 2011; 183: 1080-1091.
73. Roberts KE, Kawut SM, Krowka MJ, et al. Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. Gastroenterology 2010; 139: 130-139.
74. Zhang J, Luo B, Tang L, et al. Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. Gastroenterology 2009; 136: 1070-1080.
75. 99 mTc MAA lung scanning. Chest 2000; 118: 615-624.
76. Koksal D, Kacar S, Koksal AS, et al. Evaluation of intrapulmonary vascular dilatations with high-resolution computed thorax thomography in patients with hepatopulmonary syndrome. J Clin Gastroenterol 2002; 40: 77-83.
77. Sulieman BM, Hunsicker LG, Katz DA, et al. OPTN policy regarding prioritization of patients with hepatopulmonary syndrome: does it provide equitable organ allocation? Am J Transplant 2008; 8: 954-964.
78. Zamirian M, Aslani A, Shahrzad S. Left atrial volume: a novel predictor of hepatopulmonary syndrome. Am J Gastroenterol 2007; 102: 1392-1396.
79. Palma DT, Philips GM, Arguedas MR, et al. Oxygen desaturation during sleep in hepatopulmonary syndrome. Hepatology 2008; 47: 1257-1263.
80. Clerbaux T, Detry B, Geubel A, et al. The oxyhemoglobin dissociation curve in liver cirrhosis. Chest 2006; 129: 438-445.
81. Krowka MJ. Hepatopulmonary syndrome: monitoring at your fingertip. Dig Dis Sci 2011; 56: 1599-1600.
82. Roberts DN, Arguedas MR, Fallon MB. Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates. Liver Transpl 2007; 13: 206-214.
83. Gómez FP, Martínez-Pallí G, Barberà JA, et al. Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. Hepatology 2004; 40: 660-666.
84. Abrams GA, Jaffe CC, Hoffer PB, et al. Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. Gastroenterology 1995; 109: 1283-1288.
85. Abrams GA, Nanda NC, Dubovsky EV, et al. Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. Gastroenterology 1998; 114: 305-310.
86. Poterucha JJ, Krowka MJ, Dickson ER, et al. Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. Hepatology 1995; 21: 96-100.
87. Krowka MJ, Dickson ER, Cortese DA. Hepatopulmonary syndrome. Clinical observations and lack of therapeutic response to somatostatin analogue. Chest 1993; 104: 515-521.
88. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005; 41: 1122-1129.
89. Arguedas MR, Abrams GA, Krowka MJ, et al. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003; 37: 192-197.
90. Fallon MB, Mulligan DC, Gish RG, et al. Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. Liver Transp 2006; 12: Suppl. 3, S105-S107.
91. Soderman C, Juhlin-Dannfelt A, Lagerstrand L, et al. Ventilationperfusion relationships and central haemodynamics in patients with cirrhosis. Effects of a somatostatin analogue. J Hepatol 1994; 21: 52-57.
92. Schenk P, Madl C, Rezaie-Majd S, et al. Methylene blue improves the hepatopulmonary syndrome. Ann Intern Med 2000; 133: 701-706.
93. G-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. Hepatology 2006; 43: 1084-1091.
94. Abrams GA, Fallon MB. Treatment of hepatopulmonary syndrome with Allium sativum L. (garlic): a pilot trial. J Clin Gastroenterol 1998; 27: 232-235.
95. De BK, Dutta D, Pal SK, et al. The role of garlic in hepatopulmonary syndrome: a randomized controlled trial. Can J Gastroenterol 2010; 24: 183-188.
96. Tanikella R, Philips GM, Faulk DK, et al. Pilot study of pentoxifylline in hepatopulmonary syndrome. Liver Transpl 2008; 14: 1199-1203.
97. Gupta S, Faughnan ME, Lilly L, et al. Norfloxacin therapy for hepatopulmonary syndrome: a pilot randomized controlled trial. Clin Gastroenterol Hepatol 2010; 8: 1095-1098.